197 related articles for article (PubMed ID: 29396568)
21. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
22. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
23. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
[TBL] [Abstract][Full Text] [Related]
24. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
26. Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.
Zhang Y; Yang J; Ding M; Li L; Lu Z; Zhang Q; Zheng J
Oncol Lett; 2016 Nov; 12(5):3241-3249. PubMed ID: 27899989
[TBL] [Abstract][Full Text] [Related]
27. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
[TBL] [Abstract][Full Text] [Related]
28. A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
Zhang Q; Zhang Y; Li K; Wang H; Li H; Zheng J
PLoS One; 2015; 10(6):e0129865. PubMed ID: 26066322
[TBL] [Abstract][Full Text] [Related]
29. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Kandela I; Chou J; Chow K; ;
Elife; 2015 May; 4():. PubMed ID: 25998055
[TBL] [Abstract][Full Text] [Related]
30. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.
Li L; Yang M; Li R; Hu J; Yu L; Qian X
Anticancer Agents Med Chem; 2021; 21(7):910-918. PubMed ID: 32698755
[TBL] [Abstract][Full Text] [Related]
31. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
32. Cellular Internalization and Inhibition Capacity of New Anti-Glioma Peptide Conjugates: Physicochemical Characterization and Evaluation on Various Monolayer- and 3D-Spheroid-Based
Baranyai Z; Biri-Kovács B; Krátký M; Szeder B; Debreczeni ML; Budai J; Kovács B; Horváth L; Pári E; Németh Z; Cervenak L; Zsila F; Méhes E; Kiss É; Vinšová J; Bősze S
J Med Chem; 2021 Mar; 64(6):2982-3005. PubMed ID: 33719423
[TBL] [Abstract][Full Text] [Related]
33. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
[TBL] [Abstract][Full Text] [Related]
34. iRGD peptide as effective transporter of CuInZnxS2+x quantum dots into human cancer cells.
Przysiecka Ł; Michalska M; Nowaczyk G; Peplińska B; Jesionowski T; Schneider R; Jurga S
Colloids Surf B Biointerfaces; 2016 Oct; 146():9-18. PubMed ID: 27244046
[TBL] [Abstract][Full Text] [Related]
35. Preparation and Characterization of Dentin Phosphophoryn-Derived Peptide-Functionalized Lignin Nanoparticles for Enhanced Cellular Uptake.
Figueiredo P; Sipponen MH; Lintinen K; Correia A; Kiriazis A; Yli-Kauhaluoma J; Österberg M; George A; Hirvonen J; Kostiainen MA; Santos HA
Small; 2019 Jun; 15(24):e1901427. PubMed ID: 31062448
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
Gao W; Xiang B; Meng TT; Liu F; Qi XR
Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200
[TBL] [Abstract][Full Text] [Related]
37. Tumor-penetrating iRGD peptide inhibits metastasis.
Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
[TBL] [Abstract][Full Text] [Related]
38. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
[TBL] [Abstract][Full Text] [Related]
39. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
Cho HJ; Park SJ; Lee YS; Kim S
J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
[TBL] [Abstract][Full Text] [Related]
40. Transcatheter arterial chemoembolization (TACE) with iRGD peptide in rabbit VX2 liver tumor.
Liu X; Xie Y; Qi X; Xu K
J Cancer Res Ther; 2020; 16(7):1703-1709. PubMed ID: 33565520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
